Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Radar On Market Access: Clover Health Offers Pharmacogenomics Testing

Posted by Matt Breese on Jul 17, 2018

In-home primary care has become a de rigueur offering for Medicare Advantage (MA) organizations looking to avoid costly emergency room visits and hospital admissions. Clover Health aims to innovate the traditional multidisciplinary structure with pharmacogenomic testing that could lead to safer and more effective medication use, AIS Health reported. 
 
Clover currently serves about 600 frail, chronically ill members in its home care program, who on average have between six and 11 chronic conditions and are on 10 or more medications. The insurer in June began offering genetic testing capabilities provided by YouScript, a proprietary clinical decision support tool designed to assist in medication therapy management.
 
Read More

Topics: Industry Trends, Data & Analytics, Payer

MMIT Reality Check on Alpha-1 Antitrypsin Deficiency (Jul 2018)

Posted by Matt Breese on Jul 13, 2018

According to our recent payer coverage analysis for alpha-1 antitrypsin deficiency treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Perspectives on Value-Based Contracts

Posted by Matt Breese on Jul 12, 2018

As pharma manufacturers strive to demonstrate to payers their products' efficacy in the face of backlash against rising drug prices, one effective tactic may be to enter into value-based contracts. It's crucial for manufacturers to understand how other entities they wish to partner with approach value and to start preparing that value proposition early in the drug development process, AIS Health reported.
 
Different payers will come at value from different perspectives. "A standalone Medicare Part D plan has very different priorities than an integrated health system," says Larry Blandford, Pharm.D., an executive vice president at Precision for Value.  
 
Read More

Topics: Industry Trends, Provider, Payer

Radar On Market Access: Amazon/PillPack Deal Has Limited Effect

Posted by Matt Breese on Jul 12, 2018

Amazon recently unveiled its plan to purchase PillPack — a tech-enabled startup that offers pre-sorted dose packaging and home delivery of prescription drugs for those taking multiple medications — yet industry analysts do not appear convinced that the acquisition will have a significant effect on PBMs or health insurers, at least not in the short term, AIS Health reported.
 
"We do not expect any material impact on our financial expectations for the MCOs we cover and thus we make no change to our estimates or ratings," Credit Suisse's A.J. Rice wrote in a research note.
Read More

Topics: Industry Trends, Data & Analytics, Payer

Radar On Market Access: Centene Highlights New PBM Asset

Posted by Matt Breese on Jul 10, 2018

Amid a flurry of recent deal-making in the PBM sector, Centene Corp. highlighted the capabilities of the tech-savvy PBM it recently invested in, RxAdvance, during its June 15 investor day presentation, AIS Health reported.
 
Centene's equity investment in RxAdvance, CEO Michael Neidorff said, was made to complement the insurer's internal PBM, US Script. RxAdvance's technology and PBM cloud platform "will enable us to drive change across the care continuum," he added.
Read More

Topics: Industry Trends, Data & Analytics, Payer

MMIT Reality Check on Advanced Prostate Cancer (Jul 2018)

Posted by Matt Breese on Jul 6, 2018

According to our recent payer coverage analysis for advanced prostate cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Trends That Matter for Drug Cost

Posted by Matt Breese on Jul 5, 2018

IngenioRx, the PBM being developed by Anthem, Inc., released a drug trend report on May 31 that says Anthem's ability to manage both medical and pharmacy benefits kept the average drug cost increase at 2% for the insurer's affiliated employer-based health plans in 14 states in 2017, AIS Health reported. 

The report also found that inflation was the primary contributor to 2017 drug trends, pushing it up by 5.6%. In addition, specialty medical (21.1%) and specialty pharmacy (29.1%) accounted for 50.2% of drug spending in 2017, but by 2021 that share is expected to increase to 59.3%.

Read More

Topics: Market Access, Data & Analytics

Radar On Market Access: Pharma Can Use REMS Programs to its Advantage

Posted by Matt Breese on Jul 5, 2018

For safety concerns, the FDA can require pharmacy manufacturers to have a Risk Evaluation and Mitigation Strategy (REMS) for a therapy in order to manage those risks while still allowing people to have access to it. Although the programs may present challenges to many stakeholders, manufacturers in particular may use them to their advantage, AIS Health reported.
 
One of the top challenges that manufacturers may grapple with is the "increasing complexity of developing and administering" REMS, says Glenn Carroll, principal at Deloitte. "Many of the REMS being developed today are more rigorous to implement than what we’ve seen in the past."
Read More

Topics: Specialty, Industry Trends, Market Access, Product Release

Radar On Market Access: Gene Therapies Pose Challenges

Posted by Matt Breese on Jul 3, 2018

The FDA has multiple pathways for companies to get a review of promising drugs for conditions sorely in need of a treatment earlier in their development process than is typical, based on a surrogate endpoint. Following the FDA's approval of the first three gene therapies last year, the agency recently indicated that it will issue guidance on these products, including their potential approval based on surrogate measures. Yet this accelerated pathway holds challenges for manufacturers and payers, AIS Health reported.
 
The FDA has multiple programs that provide accelerated drug development and review: fast track designation, accelerated approval, breakthrough therapy designation and regenerative medicine advanced therapy (RMAT) designation, which was established in December 2016. The agency in November 2017 released draft guidance on applying the RMAT designation, which some gene therapies may qualify for.
 
Read More

Topics: Specialty, Industry Trends, Product Release, Payer

MMIT Reality Check on Cystic Fibrosis (Jun 2018)

Posted by Matt Breese on Jun 29, 2018

According to our recent payer coverage analysis for cystic fibrosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing